Mereo BioPharma (MREO) Operating Income (2023 - 2026)

Mereo BioPharma (MREO) has 4 years of Operating Income data on file, last reported at -$8.8 million in Q1 2026.

• On a quarterly basis, Operating Income rose 21.75% year-over-year to -$8.8 million in Q1 2026; TTM through Mar 2026 was -$37.7 million, a 22.59% increase from a year earlier, with the FY2025 full-year figure at -$40.1 million, up 15.32% from the prior year.
• Operating Income for Q1 2026 stood at -$8.8 million, down from -$8.4 million in the prior quarter.
• Over the last five years, Operating Income for MREO reached as high as -$811000.0 in Q2 2023 and fell as low as -$15.3 million in Q4 2024.
• Historically, Operating Income has averaged -$9.6 million across 4 years, with a median of -$9.9 million in 2024.
• Across the five-year window, Operating Income sank 1480.02% in 2024 and soared 45.07% in 2025, its largest moves.
• Year by year, Operating Income stood at -$7.1 million in 2023, then tumbled by 114.3% to -$15.3 million in 2024, then soared by 45.07% to -$8.4 million in 2025, then slipped by 4.48% to -$8.8 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$8.8 million in Q1 2026, -$8.4 million in Q4 2025, and -$10.0 million in Q3 2025.